Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose-Finding Study of CC-93269 in Relapsed/Refractory Multiple Myeloma
jRCT2051230108Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of alnuctamab in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and tolerability of CC-93269. Started Oct 2023; status: completed.
02
Drugs
alnuctamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2051230108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230108.